1342 - Gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit

Page last updated: 11 July 2016

Application Detail

Status

Closed

Description of Medical Service

This is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Description of Medical Condition

Outside Australia, this test is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

28 June 2013
Consultation Protocol (PDF 818 KB)
Consultation Protocol (Word 550 KB)
Closed for comments 19 July 2013

No second PASC required
Final Protocol (PDF 1158 KB)
Final Protocol (Word 488 KB)

Assessment Report

-

Public Summary Document

Final Public Summary Document (PDF 240 KB)
Final Public Summary Document (Word 138 KB)

Meetings for this Application

PASC

13 to 14 December 2012

ESC

10 to 11 October 2013

MSAC

28 November 2013